Dr. Alan Swann’s potential conflicts of interest include Elan Pharmaceuticals (research support), Bristol-Myers Squibb (consulting, speaker engagement), Lundbeck (consulting, speaker engagement), Pfizer (consulting, Data Safety Monitoring Board), Teva Pharmaceuticals (consulting, Data Safety Monitoring Board), and Merck (consulting, speaking engagements).
Dr. Maurizio Fava’s potential conflicts of interest are as follows: research support from Abbott, Alkermes, American Cyanamid, Aspect Medical Systems, AstraZeneca, Avanir, BioResearch, BrainCells, Bristol-Myers Squibb, CeNeRx BioPharma, Cephalon, Clintara, Covance, Covidien, Eli Lilly, EnVivo, Euthymics Bioscience, Forest, Ganeden Biotech, GlaxoSmithKline, Harvard Clinical Research Institute, Hoffman-LaRoche, Icon Clinical Research, i3 Innovus/Ingenix, Janssen R&D, Jed Foundation, J & J, Lichtwer Pharma GmbH, Lorex, Lundbeck, MedAvante, Methylation Sciences, the National Alliance for Research on Schizophrenia & Depression, the National Center for Complementary and Alternative Medicine, the National Institute on Drug Abuse, the National Institute of Mental Health, Neuralstem, Novartis, Organon, PamLab, Pfizer, Pharmacia-Upjohn, Pharmaceutical Research Associates, Pharmavite, PharmoRx Therapeutics, Photothera, Reckitt Benckiser, Roche, RCT Logic, Sanofi-Aventis, Shire, Solvay Pharmaceuticals, Stanley Medical Research Institute, Synthelabo, and Wyeth-Ayerst. He served as a consultant to or on the advisory boards of Abbott, Affectis, Alkermes, Amarin, Aspect Medical Systems, AstraZeneca, Auspex, Avanir, AXSOME Therapeutics, Bayer, Best Practice Project Management, BioMarin, Biovail, BrainCells, Bristol-Myers Squibb, CeNeRx BioPharma, Cephalon, Cerecor, CNS Response, Compellis, Cypress, DiagnoSearch Life Sciences, Dinippon Sumitomo, Dov, Edgemont, Eisai, Eli Lilly, EnVivo, ePharmaSolutions, EPIX, Euthymics Bioscience, Fabre-Kramer, Forest, Forum, GenOmind, GlaxoSmithKline, Grunenthal GmbH, i3 Innovus/Ingenis, Janssen, Jazz, J & J, Knoll, Labopharm, Lorex, Lundbeck, MedAvante, Merck, MSI Methylation Sciences, Naurex, Nestle Health Sciences, Neuralstem, Neuronetics, NextWave, Novartis, Nutrition 21, Orexigen Therapeutics, Organon, Otsuka, PamLab, Pfizer, PharmaStar, Pharmavite, PharmoRx Therapeutics, Precision Human Biolaboratory, Prexa, PPD, Puretech Ventures, PsychoGenics, Psylin Neurosciences, RCT Logic, Rexahn, Ridge Diagnostics, Roche, Sanofi-Aventis, Sepracor, Servier Laboratories, Schering-Plough, Solvay, Somaxon, Somerset, Sunovion, Supernus, Synthelabo, Takeda, Tal Medical, Tetragenex, TransForm, Transcept, and Vanda. He has had speaking/publishing affiliations with Adamed, Advanced Meeting Partners, the American Psychiatric Association, the American Society of Clinical Psychopharmacology, AstraZeneca, Belvoir Media Group, Boehringer Ingelheim, Bristol-Myers Squibb, Cephalon, CME Institute/Physicians Postgraduate Press, Eli Lilly, Forest, GlaxoSmithKline, Imedex, MGH Psychiatry Academy/Primedia, MGH Psychiatry Academy/Reed Elsevier, Novartis, Organon, Pfizer, PharmaStar, United BioSource, and Wyeth-Ayerst. Dr. Fava has equity holdings in Compellis and PsyBrain, and he receives copyright royalties for the MGH Cognitive and Physical Functioning Questionnaire (CPFQ), the Sexual Functioning Inventory (SFI) scale, the Antidepressant Treatment Response Questionnaire (ATRQ), the Discontinuation–Emergent Signs & Symptoms (DESS) Scale, the Symptoms of Depression Questionnaire (SDQ), and the SAFER criteria interview, and he has patents for SPCD and for a combination of ketamine and scopolamine in major depressive disorder.
Drs. Joyce Tsai, Yongcai Mao, Andrei Pikalov, and Antony Loebel are employees of Sunovion Pharmaceuticals Inc.
Fava, M, Rosenbaum, JF. Anger attacks in depression.
. 1998; 8(Suppl 1): 59–63.
Perlis, RH, Fraguas, R, Fava, M, et al. Prevalence and clinical correlates of irritability in major depressive disorder: a preliminary report from the Sequenced Treatment Alternatives to Relieve Depression Study. J Clin Psychiatry. 2005; 66(2): 159–166; quiz 147, 273–274.
Benazzi, F. Possible bipolar nature of irritability in major depressive disorder. J Clin Psychiatry. 2005; 66(8): 1072; author reply 1073.
Winkler, D, Pjrek, E, Kasper, S. Anger attacks in depression: evidence for a male depressive syndrome. Psychother Psychosom. 2005; 74(5): 303–307.
Perlis, RH, Fava, M, Trivedi, MH, et al. Irritability is associated with anxiety and greater severity, but not bipolar spectrum features, in major depressive disorder. Acta Psychiatr Scand. 2009; 119(4): 282–289. Epub ahead of print Feb 5. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3312008/.
Fava, M, Hwang, I, Rush, AJ, et al. The importance of irritability as a symptom of major depressive disorder: results from the National Comorbidity Survey Replication. Mol Psychiatry. 2010; 15(8): 856–867. Epub ahead of print Mar 10, 2009. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3012558/.
American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 5th ed. Washington, DC: American Psychiatric Association; 2013.
Zisook, S, Rush, AJ, Albala, A, et al. Factors that differentiate early vs. later onset of major depression disorder. Psychiatry Res. 2004; 129(2): 127–140.
Benazzi, F, Akiskal, H. Irritable-hostile depression: further validation as a bipolar depressive mixed state. J Affect Disord. 2005; 84(2–3): 197–207.
Perlis, RH, Uher, R, Ostacher, M, et al. Association between bipolar spectrum features and treatment outcomes in outpatients with major depressive disorder. Arch Gen Psychiatry. 2011; 68(4): 351–360. Epub ahead of print Dec 6, 2010. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3794668/.
Judd, LL, Schettler, PJ, Akiskal, H, et al. Prevalence and clinical significance of subsyndromal manic symptoms, including irritability and psychomotor agitation, during bipolar major depressive episodes. J Affect Disord. 2012; 138(3): 440–448. Epub ahead of print Feb 6. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3677770/pdf/nihms468685.pdf.
Fisher, LB, Fava, M, Doros, GD, et al. The role of anger/hostility in treatment-resistant depression: a secondary analysis from the ADAPT–A study. J Nerv Ment Dis. 2015; 203(10): 762–768.
Pae, CU, Vohringer, PA, Holtzman, NS, et al. Mixed depression: a study of its phenomenology and relation to treatment response. J Affect Disord. 2012; 136(3): 1059–1061.
Judd, LL, Akiskal, HS. The prevalence and disability of bipolar spectrum disorders in the US population: re-analysis of the ECA database taking into account subthreshold cases. J Affect Disord. 2003; 73(1–2): 123–131.
Angst, J, Cui, L, Swendsen, J, et al. Major depressive disorder with subthreshold bipolarity in the National Comorbidity Survey Replication. Am J Psychiatry. 2010; 167(10): 1194–1201. Epub 2010 Aug 16. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3145248/.
Benazzi, F, Akiskal, HS. Psychometric delineation of the most discriminant symptoms of depressive mixed states. Psychiatry Res. 2006; 141(1): 81–88.
Hoertel, N, Le Strat, Y, Angst, J, et al. Subthreshold bipolar disorder in a US national representative sample: prevalence, correlates, and perspectives for psychiatric nosography. J Affect Disord. 2013; 146(3): 338–347. Epub ahead of print Oct 3, 2012.
McIntyre, RS, Soczynska, JK, Cha, DS, et al. The prevalence and illness characteristics of DSM–5-defined “mixed feature specifier” in adults with major depressive disorder and bipolar disorder: results from the International Mood Disorders Collaborative Project. J Affect Disord. 2014; 172: 259–264. Epub ahead of print Oct 12.
Perugi, G, Angst, J, Azorin, JM, et al. Mixed features in patients with a major depressive episode: the BRIDGE–II–MIX study. J Clin Psychiatry. 2015; 76(3): e351–e358.
Ishibashi, T, Horisawa, T, Tokuda, K, et al. Pharmacological profile of lurasidone, a novel antipsychotic agent with potent 5-hydroxytryptamine (5-HT7) and 5-HT1A receptor activity. J Pharmacol Exp Ther. 2010; 334(1): 171–181. Available at: http://jpet.aspetjournals.org/content/334/1/171.long.
Nakamura, M, Ogasa, M, Guarino, J, et al. Lurasidone in the treatment of acute schizophrenia: a double-blind, placebo-controlled trial. J Clin Psychiatry. 2009; 70(6): 829–836. Epub ahead of print Jun 2.
Loebel, A, Cucchiaro, J, Xu, J, Sarma, K, Pikalov, A, Kane, JM. Effectiveness of lurasidone vs. quetiapine XR for relapse prevention in schizophrenia: a 12-month, double-blind, noninferiority study. Schizophr Res. 2013; 147(1): 95–102. Epub ahead of print Apr 11. Available at: http://www.schres-journal.com/article/S0920-9964(13)00159-X/pdf.
Suppes, T, Silva, R, Cucchiaro, J, et al. Lurasidone for the treatment of major depressive disorder with mixed features: a randomized, double-blind, placebo-controlled study. Am J Psychiatry. 2016; 173(4): 400–407. Epub ahead of print Nov 10, 2015.
First, MB, Williams, J, Spitzer, RL, et al. Structured Clinical Interview for DSM–IV–TR Axis I Disorders, Clinical Trials Version (SCID–CT). New York: Biometrics Research, New York State Psychiatric Institute; 2007.
Montgomery, SA, Åsberg, M. A new depression scale designed to be sensitive to change. Br J Psychiatry. 1979; 134: 382–389.
Guy, W. ECDEU Assessment Manual for Psychopharmacology. Publication no. ADM 76–338. Washington, DC: U.S. Department of Health, Education, and Welfare; 1976: esp. 218–222.
Young, RC, Biggs, JT, Ziegler, VE, et al. A rating scale for mania: reliability, validity, and sensitivity. Br J Psychiatry. 1978; 133: 429–435.
Smith, DJ, Forty, L, Russell, E, et al. Sub-threshold manic symptoms in recurrent major depressive disorder are a marker for poor outcome. Acta Psychiatr Scand. 2009; 119(4): 325–329. Epub ahead of print Dec 16, 2009.
Ionescu, DF, Fava, M, Kim, DJ, Baer, L, Shelton, RC, Cusin, C. A placebo-controlled crossover study of iloperidone augmentation for residual anger and irritability in major depressive disorder. Ther Adv Psychopharmacol. 2016; 6(1): 4–12. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4749740/.
Khan, SA, Revicki, DA, Hassan, M, et al. Assessing the reliability and validity of the Sheehan Irritability Scale in patients with major depressive disorder. J Clin Psychiatry. 2016; 77(8): 1080–1086.